The Genetics Company Inc. enters distributorship agreement with Stratech Scientific Ltd.

25-Feb-2009 - Ireland

The Genetics Company Inc. announced the closing of a distributorship agreement with Stratech Scientific Ltd. Within the scope of this agreement, The Genetics Company will supply Stratech with its beta-Amyloid (Aβ) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in the UK and Ireland.

Sharon Young, Director at Stratech Scientific Ltd. commented: “The Genetics Company's high quality research and diagnosis products will enable us to participate in and further develop the emerging field of neurodegenerative diseases in the UK and Ireland, especially in the areas of academic and industrial research as well as for in vitro diagnosis”.

Dr. Matyas Vegh, CEO at The Genetics Company added: “With Stratech we are pleased to have found the ideal partner to make our products available to customers in the UK and Ireland. This cooperation enables us to cover a highly attractive research and health care market in Europe".

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics